Based on the Atossa Genetics Inc stock forecast from 2 analysts, the average analyst target price for Atossa Genetics Inc is USD 7.00 over the next 12 months. Atossa Genetics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Atossa Genetics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Atossa Genetics Inc’s stock price was USD 0.73. Atossa Genetics Inc’s stock price has changed by -1.46% over the past week, -12.05% over the past month and -43.40% over the last year.
No recent analyst target price found for Atossa Genetics Inc
No recent average analyst rating found for Atossa Genetics Inc
Company Overview Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Read Less
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolit...Read More
Frequently Asked Questions About Atossa Genetics Inc (ATOS) Stock
Based on ratings from 2 analysts Atossa Genetics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATOS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ATOS is USD 7.00 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ATOS's stock to indicate if its overvalued.
The last closing price of ATOS's stock was USD 0.73.
The most recent market capitalization for ATOS is USD 0.10B.
Based on targets from 2 analysts, the average taret price for ATOS is projected at USD 7.00 over the next 12 months.
This means that ATOS's stock price may go up by +858.64% over the next 12 months.
We can't find any ETFs which contains Atossa Genetics Inc's stock.
As per our most recent records Atossa Genetics Inc has 12 Employees.
Atossa Genetics Inc's registered address is 107 Spring Street, Seattle, WA, United States, 98104.
You can get more information about it from Atossa Genetics Inc's website at https://www.atossatherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Atossa Genetics Inc (ATOS) Stock
Based on ratings from 2 analysts Atossa Genetics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATOS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ATOS is USD 7.00 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ATOS's stock to indicate if its overvalued.
The last closing price of ATOS's stock was USD 0.73.
The most recent market capitalization for ATOS is USD 0.10B.
Based on targets from 2 analysts, the average taret price for ATOS is projected at USD 7.00 over the next 12 months.
This means that ATOS's stock price may go up by +858.64% over the next 12 months.
We can't find any ETFs which contains Atossa Genetics Inc's stock.
As per our most recent records Atossa Genetics Inc has 12 Employees.
Atossa Genetics Inc's registered address is 107 Spring Street, Seattle, WA, United States, 98104.
You can get more information about it from Atossa Genetics Inc's website at https://www.atossatherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATOS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
